HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 293/5/F1577    most recent 00463.2006v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (1) Citing Articles via Google Scholar Google Scholar Articles by Perwad, F. Articles by Portale, A. A. Search for Related Content PubMed PubMed Citation Articles by Perwad, F. Articles by Portale, A. A.

Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1-hydroxylase expression in vitro

¹Pediatrics, University of California San Francisco, San Francisco, California; and ²Pediatrics and Human Genetics, McGill University, Montreal, Quebec, Canada

Submitted 20 November 2006 ; accepted in final form 9 August 2007

Fibroblast growth factor-23 (FGF-23) is critical to the pathogenesis of a distinct group of renal phosphate wasting disorders: tumor-induced osteomalacia, X-linked hypophosphatemia, and autosomal dominant and autosomal recessive hypophosphatemic rickets. Excess circulating FGF-23 is responsible for their major phenotypic features which include hypophosphatemia due to renal phosphate wasting and inappropriately low serum 1,25(OH)₂D concentrations. To characterize the effects of FGF-23 on renal sodium-phosphate (Na/P_i) cotransport and vitamin D metabolism, we administered FGF-23(R176Q) to normal mice. A single injection (0.33 µg/g body wt) induced significant hypophosphatemia, 20 and 29% decreases (P < 0.001) in brush-border membrane (BBM) Na/P_i cotransport at 5 and 17 h after injection, respectively, and comparable decreases in the abundance of type IIa Na/P_i cotransporter protein in BBM. Multiple injections (6, 12, and 24 µg/day for 4 days) induced dose-dependent decreases (38, 63, and 75%, respectively) in renal abundance of 1-hydroxylase mRNA (P < 0.05). To determine whether FGF-23(R176Q) exerts a direct action on 1-hydroxylase gene expression, we examined its effects in cultured human (HKC-8) and mouse (MCT) renal proximal tubule cells. FGF-23(R176Q) (1 to 10 ng/ml) induced a dose-dependent decrease in 1-hydroxylase mRNA with a maximum suppression of 37% (P < 0.05). Suppression was detectable after 6 h of exposure and maximal after 21 h. In MCT cells, FGF-23(R176Q) suppressed 1-hydroxylase mRNA and activated the ERK1/2 signaling pathway. The MAPK inhibitor PD98059 effectively abolished FGF-23-induced suppression of 1-hydroxylase mRNA by blocking signal transduction via ERK1/2. These novel findings provide evidence that FGF-23 directly regulates renal 1-hydroxylase gene expression via activation of the ERK1/2 signaling pathway.

bone and mineral homeostasis; hypophosphatemic syndromes

This article has been cited by other articles:

				S. Liu, L. Vierthaler, W. Tang, J. Zhou, and L. D. Quarles FGFR3 and FGFR4 Do not Mediate Renal Effects of FGF23 J. Am. Soc. Nephrol., December 1, 2008; 19(12): 2342 - 2350. [Abstract] [Full Text] [PDF]

				J. Danziger The bone-renal axis in early chronic kidney disease: an emerging paradigm Nephrol. Dial. Transplant., September 1, 2008; 23(9): 2733 - 2737. [Full Text] [PDF]

				W. Al-Badr and K. J. Martin Vitamin D and Kidney Disease Clin. J. Am. Soc. Nephrol., September 1, 2008; 3(5): 1555 - 1560. [Abstract] [Full Text] [PDF]

				S. Goto, H. Komaba, and M. Fukagawa Pathophysiology of parathyroid hyperplasia in chronic kidney disease: preclinical and clinical basis for parathyroid intervention NDT Plus, August 1, 2008; 1(suppl_3): iii2 - iii8. [Abstract] [Full Text] [PDF]